North America dominates theglobal therapeutic drug monitoring market
North America holds the dominantposition in TherapeuticDrug Monitoring Market, owing to robust health care infrastructure, highawareness for treatment regime and increasing patient awareness regardingadverse drug reaction (ADR). According to 2013 survey by Medical ExpenditurePanel published in Scientific American, 1 in 7 American adult consumeAnti-Psychotic drug, a class of drugs which requires TDM. Stringent governmentregulations regarding safe medication practices especially with drugs havingnarrow therapeutic range would propel growth therapeutic drug monitoring.Moreover, increasing adoption of instruments such as monitors and analyticequipment, reagents, and diagnostics tools for drug monitoring is driving thegrowth of therapeutic drug monitoring market.
However, difficulty inreimbursement bars the widespread usage of TDM, as often the cost associatedwith TDM is high. Furthermore, insufficient infrastructure and skilled manpoweris restraining the growth of the market in emerging economies.
Therapeutic drug monitoring is amultidisciplinary practice of measuring drug amount in bloodstream to maintainits effective concentration. It is used to maximize efficacy of drug, avoidtoxicity and adverse drug reactions (ADR), facilitate dose adjustment accordingpatient requirement, and to identify therapeutic failure. It is used especiallyfor drugs characterized by narrow therapeutic window, drugs that are highlyprotein bound and those in which the metabolite might be toxic.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1241
Physicians and hospitals usetherapeutic drug monitoring to maximize the clinical benefits of the drug byminimizing the toxic side effects thereby improving the quality of life for thepatients.
Personalized medicine andadvanced technologies such as assay performance and drug monitoring to fuel thegrowth of therapeutic drug monitoring market
Personalized medicine is drivingthe growth of therapeutic drug monitoring market, owing to increasing demandfor better treatment outcome with minimum side effects from the medication. Forinstance, TDM is majorly used for anti-cancer drugs monitoring for whichstandard guidelines are recommended by many oncology Journal and associations,one of them being the European Journal of Oncology. Moreover, advancedtreatment therapies such pharmacogenomics, gene testing, and proteomics is furtherexpected to boost the growth of market. Increasing antimicrobial resistance isone of the key factor driving the growth of TDM market. According to WHOFactsheet 2017, antimicrobial resistance is one of the leading cause of death.For instance, according to WHO factsheet, around 4,80,000 multi-drug resistanceTB cases were reported, which is creating an opportunity for physicians tooptimize or monitor the drug therapies through TDM.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/therapeutic-drug-monitoring-market-1241
Organ transplant procedures arealso propelling the growth of therapeutic drug monitoring market.Immunosuppressant drugs are basic treatment for organ transplant to avoidrejection of transplanted organ by body, which requires TDM to avoid ADR andside effects. Asia Pacific is a promising region for organ transplant due to increasedawareness and infrastructure availability. According to Waters CorporationBlog, China witnessed 35% y-o-y increase in organ transplant in the first 4months of 2017. There is a growing trend of clinical research organizationsbeing shifted to cost effective Asia Pacific region for bioequivalence study ofgeneric drugs on account of low cost of processes in this region. Moreover,advances in the field of biomedical technology such as nano biosensors andimplantable devices are expected to boost the growth of therapeutic drugmonitoring market. Advancement in tools for TDM such as assay kits,chromatography columns, spectrometry, and alternative matrices such asinterstitial fluid provide continuous real time monitoring of the therapeuticdrug through Probe Scientific’s new MicroEye Technology.
Key players in the globaltherapeutic drug monitoring market include Roche Diagnostics, Thermo FisherScientific, Bio Rad Laboratories, Siemens Healthcare Diagnostics, BeckmannCoulter, and Abbott Diagnostics. In 2016, Danaher Corporation, parent company forBeckman Coulter acquired Cepheid at US$ 4 billion to strengthen company’sdiagnostic portfolio.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1241
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
